Hims & Hers stock was trading around $19 to $20 on Tuesday as investors weighed a fast-moving shift in the company’s weight-loss business and its push into longer-term health products. The move comes about a month after Novo Nordisk backed away from its patent lawsuit against Hims & Hers and agreed to partner with the company to distribute branded Wegovy and Ozempic through Hims.
That deal changed the tone around the company almost overnight. Novo’s retreat removed a legal cloud that had hovered over Hims for months, and it also opened a new path for a business that had been seen mainly through the lens of compounded semaglutide. In a recent post, Hims chief executive Andrew Dudum said the company was on track to reach 100,000 Wegovy prescriptions a month, a scale that would have seemed far-fetched when the lawsuit was still hanging over the stock.
The numbers matter because they show how quickly the story around Hims stock has moved from courtroom risk to commercial momentum. Investors had feared Big Pharma would eventually beat Hims in court over compounded semaglutide, and the old legal overhang centered on whether those weight-loss drugs were only a temporary workaround after the FDA moved past the shortage phase. With the lawsuit dropped and Novo now a partner, that threat has receded for the moment.
But weight loss is only the front door. Hims has launched a new Labs initiative focused on personalized biomarkers, and the company is moving into peptides as part of a broader health platform it wants to build over time. That push lines up with a bigger consumer shift as search interest for peptides surges and the longevity trend moves into the mainstream, turning a niche wellness concept into a larger commercial category.
The tension now is whether Hims can turn that momentum into something more durable than a one-product trade. The stock is still being priced around the promise of growth, but the next phase depends on whether the company can keep prescriptions rising while convincing investors that labs, biomarkers and peptides are not just add-ons. For now, the market is giving Hims credit for escaping the legal trap and for reaching deeper into a health market that is expanding beyond weight loss.